277 related articles for article (PubMed ID: 17537677)
1. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Pine PR; Chang B; Schoettler N; Banquerigo ML; Wang S; Lau A; Zhao F; Grossbard EB; Payan DG; Brahn E
Clin Immunol; 2007 Sep; 124(3):244-57. PubMed ID: 17537677
[TBL] [Abstract][Full Text] [Related]
2. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
3. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Scott DL
Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
[TBL] [Abstract][Full Text] [Related]
4. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
5. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.
Zhu Y; Herlaar E; Masuda ES; Burleson GR; Nelson AJ; Grossbard EB; Clemens GR
Toxicol Appl Pharmacol; 2007 Jun; 221(3):268-77. PubMed ID: 17490694
[TBL] [Abstract][Full Text] [Related]
6. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.
Cha HS; Boyle DL; Inoue T; Schoot R; Tak PP; Pine P; Firestein GS
J Pharmacol Exp Ther; 2006 May; 317(2):571-8. PubMed ID: 16452391
[TBL] [Abstract][Full Text] [Related]
7. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Zhang Z; Cao C; Sun S; Xu Q
Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
[TBL] [Abstract][Full Text] [Related]
8. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
9. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
10. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
11. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Platt AM; Benson RA; McQueenie R; Butcher JP; Braddock M; Brewer JM; McInnes IB; Garside P
Rheumatology (Oxford); 2015 Jan; 54(1):169-77. PubMed ID: 25065010
[TBL] [Abstract][Full Text] [Related]
12. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
[TBL] [Abstract][Full Text] [Related]
13. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
14. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
[TBL] [Abstract][Full Text] [Related]
15. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
Spalton JC; Mori J; Pollitt AY; Hughes CE; Eble JA; Watson SP
J Thromb Haemost; 2009 Jul; 7(7):1192-9. PubMed ID: 19422460
[TBL] [Abstract][Full Text] [Related]
16. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey.
Sweeny DJ; Li W; Grossbard E; Lau DT
Xenobiotica; 2010 Jun; 40(6):415-23. PubMed ID: 20415544
[TBL] [Abstract][Full Text] [Related]
17. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
[TBL] [Abstract][Full Text] [Related]
18. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
19. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation.
Matsubara S; Koya T; Takeda K; Joetham A; Miyahara N; Pine P; Masuda ES; Swasey CH; Gelfand EW
Am J Respir Cell Mol Biol; 2006 Apr; 34(4):426-33. PubMed ID: 16339999
[TBL] [Abstract][Full Text] [Related]
20. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]